3-苄氧基苯甲酰肼 | 228419-13-4

• 物质功能分类: 化学试剂 - 有机试剂 - 芳烃
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-苄氧基苯甲酰肼
• 中文别名: 3-苄氧基苯酰肼
• 英文名称: 3-(benzyloxy)benzohydrazide
• 英文别名: 3-Benzyloxybenzhydrazide；3-phenylmethoxybenzohydrazide
• CAS: 228419-13-4
• 化学式: C₁₄H₁₄N₂O₂
• mdl: MFCD01310784
• 分子量: 242.277
• InChiKey: JKJQCSNZIBXALH-UHFFFAOYSA-N

物化性质

• 熔点：
  113 °C
• 密度：
  1.201±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.071
• 拓扑面积：
  64.4
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 安全说明：
  S26,S36/37/39
• 危险类别码：
  R36/37/38
• 海关编码：
  2928000090
• 储存条件：
  室温

反应信息

• 作为反应物：
  描述：

  3-苄氧基苯甲酰肼 在 一水合肼 作用下， 以 甲醇 、 甲苯 为溶剂， 反应 28.0h， 生成 2-carbohydrazide
  参考文献：
  名称：

  基于结构的非肽，碳酰肼基组织蛋白酶K抑制剂的结构设计。

  摘要：

  使用基于与组织蛋白酶K复合的基于氨基酸的活性位点跨越抑制剂的X射线晶体结构的结合模型，开发了Cbz-亮氨酸模拟物，最终导致设计了一种有效的不含组织蛋白酶K的组织蛋白酶K抑制剂。氨基酸成分。这些由α-取代的联苯乙酰基代替Cbz-亮氨酸部分组成的模拟物有效模拟了对抑制剂结合很重要的Cbz-亮氨酸部分的所有方面。抑制剂与组织蛋白酶K的复合物的质谱分析证实了抑制剂的预测结合方向，其结果与酶的酰化作用和抑制剂在活性位点S'侧结合的酰基肼部分的损失相符。 。发现结合模型非常可预测相对抑制剂效力以及抑制剂结合的方向。这些结果增强了涉及基于结构的设计，抑制剂合成和评估非肽抑制剂发现的迭代循环策略的有效性。

  DOI：

  10.1016/s0968-0896(99)00010-3
• 作为产物：
  描述：

  3-羟基苯甲酸乙酯 在 potassium carbonate 、 一水合肼 作用下， 以 乙醇 、 丙酮 为溶剂， 反应 31.0h， 生成 3-苄氧基苯甲酰肼
  参考文献：
  名称：

  Synthesis and Biological Screening of 2-Substituted 5,6-Dihydro-5-oxo- 4H-1,3,4-oxadiazine-4-propanenitriles and of Their Intermediates

  摘要：

  To evaluate the effect of substituents on biological activities of electron-rich N-containing heterocycles, the variably 2-substituted 5,6-dihydro-5-oxo-4H-1,3,4-oxadiazine-4-propanenitriles 26-33 were synthesized and evaluated for antibacterial, antifungal, and enzyme-inhibition activities. The target compounds were obtained from alkyl 4- or 3-hydroxy benzoates 1 and 2, respectively, and from methyl indoleacetate 3. The phenolic OH group of benzoates I and 2 were substituted with p-toluenesulfonyl ( --> 4 and 5), benzoyl ( 6 and 7), and benzyl groups ( 8 and 9) and then converted to 5,6-dihydro-5-oxo-4H-1,3,4-oxadiazine-4-propanenitriles. To establish structure-activity relationships (SAR), a pharmacological screening of the intervening intermediates was also conducted, which revealed that the intermediate hydrazide 11 possesses significant antimicrobial and MAO-A inhibiting properties and intermediates 12,24,28, and 29 appreciable antifungal activities. Compound 7 inhibits a-chymotrypsin.

  DOI：

  10.1002/1522-2675(200202)85:2<559::aid-hlca559>3.0.co;2-a

文献信息

• Synthesis and in vitro leishmanicidal activity of some hydrazides and their analogues
  作者：Khalid Mohammad Khan、Maimona Rasheed、Zia Ullah、Safdar Hayat、Farhana Kaukab、M.Iqbal Choudhary、Atta ur-Rahman、Shahnaz Perveen

  DOI：10.1016/s0968-0896(02)00611-9

  日期：2003.4

  Twenty-one hydrazides were synthesized by treating different esters with hydrazine hydrate. Substituted hydrazides were obtained by treating hydrazides with alkyl/aryl/acyl halides. Some of these compounds exhibit potential in vitro leishmanicidal activity. The structures of all the synthesized compounds were confirmed by spectroscopic analysis.

  通过用水合肼处理不同的酯来合成二十一个酰肼。通过用烷基/芳基/酰基卤化物处理酰肼得到取代的酰肼。这些化合物中的某些表现出潜在的体外杀菌作用。所有合成化合物的结构通过光谱分析确认。
• .BETA.-N-Cyanoethyl Acyl Hydrazide Derivatives: A New Class of .BETA.-Glucuronidase Inhibitors.
  作者：Khalid Mohammed Khan、Shahida Shujaat、Shagufta Rahat、Safdar Hayat、Atta-ur-Rahman、Muhammad Iqbal Choudhary

  DOI：10.1248/cpb.50.1443

  日期：——

  Eight new β-N-substituted acyl hydrazides along with their corresponding acyl derivatives were synthesized and screened for in vitro β-glucuronidase inhibition and found to be active against the enzyme. All of these compounds were found to be noncompetitive inhibitors except for N′-(2-cyanoethyl)-4-hydroxy benzohydrazide (10), which was found to be an uncompetitive inhibitor. Structure–activity relationship studies indicated that the benzyloxy group present in compounds 12 and 13 is responsible for the β-glucuronidase inhibition activity.

  合成了八种新的β-N-取代酰肼及其相应的酰基衍生物，并对它们进行了体外β-葡萄糖苷酶抑制活性筛选，发现它们对酶具有活性。除了N'-(2-氰乙基)-4-羟基苯甲酼肼（10）被发现是非竞争性抑制剂外，所有这些化合物都被发现是非竞争性抑制剂。结构-活性关系研究表明，化合物12和13中的苄氧基是导致β-葡萄糖苷酶抑制活性的原因。
• Substitution of terminal amide with 1 H -1,2,3-triazole: Identification of unexpected class of potent antibacterial agents
  作者：Fangchao Bi、Shengli Ji、Henrietta Venter、Jingru Liu、Susan J. Semple、Shutao Ma

  DOI：10.1016/j.bmcl.2018.02.001

  日期：2018.3

  3-Methoxybenzamide (3-MBA) derivatives have been identified as novel class of potent antibacterial agents targeting the bacterial cell division protein FtsZ. As one of isosteres for the amide group, 1,2,3-triazole can mimic the topological and electronic features of the amide, which has gained increasing attention in drug discovery. Based on these considerations, we prepared a series of 1H-1,2,3-triazole-containing

  3-甲氧基苯甲酰胺（3-MBA）衍生物已被确定为针对细菌细胞分裂蛋白FtsZ的新型有效抗菌剂。作为酰胺基团的等排体之一，1,2,3-三唑可以模拟酰胺的拓扑和电子特征，这在药物开发中已引起越来越多的关注。基于这些考虑，我们通过用三唑等位取代末端酰胺，制备了一系列含有1 H -1,2,3-三唑的3-MBA类似物，从而提高了抗菌活性。这项研究证明了发展1 H -1,2,3-三唑基作为末端酰胺模拟元件的可能性，该模拟元件能够保持和调节酰胺相关的生物活性。令人惊讶的是，这些新的1观察到含有H -1,2,3-三唑的类似物，这可能为开发抗菌剂打开新的机会。
• Developing novel classes of protein kinase CK1δ inhibitors by fusing [1,2,4]triazole with different bicyclic heteroaromatic systems
  作者：Ilenia Grieco、Maicol Bissaro、Davide Benedetto Tiz、Daniel I. Perez、Conception Perez、Ana Martinez、Sara Redenti、Elena Mariotto、Roberta Bortolozzi、Giampietro Viola、Giorgio Cozza、Giampiero Spalluto、Stefano Moro、Stephanie Federico

  DOI：10.1016/j.ejmech.2021.113331

  日期：2021.4

  become a possible therapeutic target for these conditions. 5,6-fused bicyclic heteroaromatic systems that resemble adenine of ATP represent optimal scaffolds for the development of a new class of ATP competitive CK1δ inhibitors. In particular, a new series of [1,2,4]triazolo[1,5-c]pyrimidines and [1,2,4]triazolo[1,5-a][1,3,5]triazines was developed. Some crucial interactors have been identified, such

  蛋白激酶CK1 δ表达和活性涉及在包括神经炎症和神经变性疾病不同病理情况。出于这个原因，蛋白激酶CK1 δ已经成为这些条件的可能的治疗靶标。5,6-稠类似于ATP的腺嘌呤代表最佳的支架为一类新的ATP竞争力的CK1的发展双环杂系统δ抑制剂。特别是，一系列新的[1,2,4]三唑[1,5- c ]嘧啶和[1,2,4]三唑[1,5- a ]研制了[1,3,5]三嗪。已经鉴定出一些关键的相互作用子，例如能够与[1,2,4] triazolo [1,5- c的5和7位上的铰链区残基相互作用的游离氨基的存在。]嘧啶和[1,2,4]三唑[1,5- a分别[] [1,3,5]三嗪支架；或在两个核的2位上都存在3-羟苯基或3,5-二羟苯基部分。分子模型研究确定了抑制剂-蛋白质识别过程中涉及的关键相互作用，这些相互作用与所述结构-活性关系适当相符。考虑到CK1蛋白激酶参与各种病理，特别是中枢神经系统的病理这一
• [EN] NOVEL SUBSTITUTED PYRAZOLES, 1,2,4-OXADIAZOLES, AND 1,3,4-OXADIAZOLES<br/>[FR] NOUVEAUX PYRAZOLES SUBSTITUÉS, 1,2,4-OXADIAZOLES, ET 1,3,4-OXADIAZOLES
  申请人：MERCK & CO INC

  公开号：WO2009146343A1

  公开（公告）日：2009-12-03

  The present invention relates to novel amyloid binding compounds and methods for measuring effects of the compounds, by measuring changes of amyloid plaque level in living patients. More specifically, the present invention relates to a method of using the compounds of this invention as tracers in positron emission tomography (PET) imaging to study amyloid deposits in brain in vivo to allow diagnosis of Alzheimer's disease. Thus, the present invention relates to use of the novel amyloid binding compounds as a diagnostic. The invention further relates to a method of measuring clinical efficacy of Alzheimer's disease therapeutic agents. Specifically, the present invention relates to novel aryl or heteroaryl substituted pyrazole derivatives, compositions, and therapeutic uses and processes for making such compounds.

  本发明涉及新型淀粉样蛋白结合化合物和测量这些化合物效果的方法，通过测量活体患者淀粉样斑块水平的变化。更具体地说，本发明涉及一种利用本发明化合物作为示踪剂在正电子发射断层扫描（PET）成像中研究活体大脑中淀粉样沉积以进行阿尔茨海默病诊断的方法。因此，本发明涉及将新型淀粉样蛋白结合化合物用作诊断的用途。该发明还涉及一种测量阿尔茨海默病治疗药物临床疗效的方法。具体而言，本发明涉及新型芳基或杂环芳基取代的吡唑衍生物、组成物和制备此类化合物的治疗用途和方法。